|
Overall, 2009 was a very good year for Cosmo. In an environment where a number of biotech companies have struggled, we were able to deliver on our objectives. |
 |
Our results for the year ended 31 December 2009. |
 |
 |
|
|
 |
|
Currently, Cosmo has two products on the market, five in clinical trials and a further three in preclinical development. |
|
|
| |
|
|
|
|
|
Key events, facts and figures of 2009. |
|
Our corporate governance principles and codes. |
| |
|
|
|
|
|
